Your weekly recap of news and analysis from the psychedelic sector.
Psychedelic Bulletin: Field Trip Set to List on Nasdaq; Cybin to List on NYSE American
This week: Toronto-based Field Trip announces Nasdaq uplisting; Cybin looks set to list on NYSE American; and more…
Psychedelic Bulletin: Third Psychedelics ETF Expected to Launch; Tracking Psychedelic Drug Policy Reform; One Direction for atai
This week: a third psychedelics ETF is expected to launch soon; One Direction’s Liam Payne invests in atai; our latest resource tracks psychedelic drug policy reform; and more…
Psychedelic Bulletin: Compass Announces New Collaboration; MindMed Partners with Real-World Data Provider; Yale Researchers Show Psilocybin Increases Nueronal Connections
This week: Researchers at Yale have shown that psilocybin generates a 10% increase in neuronal connections in mice; Compass is set to collaborate with the NHS and King’s College London; MindMed strikes partnership with Datavant; and more…
Psychedelic Bulletin: Harvard Law School Launches Psychedelics Project; California Decrim. Bill Clears Latest Hurdle; LSD for Food Allergies?
This week: Harvard Law School has launched a 3-year project promotion safety, innovation, equity and access in the psychedelic space; CA moves closer to decrim.; and, a patent is granted on LSD for food allergies.
Psychedelic Bulletin: Ex-FDA Psychiatry Director Joins Cybin as Advisor; Texas Approves Psychedelics Studies; and more…
This week: Texas approves psychedelic research via bill; ex-FDA psychiatry director joins Cybin Inc. as advisor; atai IPO fails to lift market.
Psychedelic Bulletin: atai IPOs on Nasdaq; Cybin to Target Anxiety Indications; Next Steps for California Decrim. Bill
This week: atai IPOs on the Nasdaq with $3bn valuation; Cybin targets anxiety indications; California decrim. bill gets hearing date; and more…